Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aprotinin for transfusion reduction in thoracic cancer surgery
2005-004689-18Phase 3Terminated
- Sponsor
- Bayer
- Start
- Feb 2006
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in bronchial carcinoma and esophageal cancer comparing Trasylol with Placebo (2 arms). Primary endpoints: Percent of patients requiring blood transfusion, Blood loss reduction and 1 more. Started Feb 2006; status: terminated.
02
Drugs
aprotinin
03
Conditions
bronchial carcinomaesophageal cancer
Beyond the preview
Go deeper on 2005-004689-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004689-18.